Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limertinib plus iodine-125 seed implantation for EGFR-mutant NSCLC oligoprogression
ChiCTR2500110139Phase 4Not yet recruiting
- Sponsor
- Hebei General Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of limertinib in non-small cell lung cancer (NSCLC), sponsored by Hebei General Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
limertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500110139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110139.